Skip to main content
OpenTrials
Completed

NCT Number: NCT03992313

Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia

Objectives Principal objective: to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population aged more than 40 years old in Cambodia Secondary objectives

* To compare the HCV antibody testing uptake between the 2 arms for the eligible population * To compare the active case detection rate between the 2 arms for the eligible population * To compare the linkage to care between the 2 arms for those with active infection * To compare the cost-effectiveness of the two strategies * To evaluate the treatment uptake * To evaluate the effectiveness and safety of a 12-week dual-therapy of direct-acting antiviral (DAA) treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chrey Vean Health Center, Kampong Cham, Cambodia

Loading trial locations.

About this study

Methodology: two-arms cluster-randomized controlled trial. Clusters are defined as a group of 50 households

Expected enrolment : 8000 patients in 160 clusters, 80 villages in each of the 2 provinces (Kompong Cham and Siem Reap)

Intervention

Arm 1: Facility-based testing intervention A team of community Health Workers (CHWs) will prepare a schedule to visit the selected villages and provide mass information on the possibility to be tested in health centers for HCV infection. Information will be provided using information sheet and a dedicated leaflet. If the participant agrees to participate, the signed consent form will be collected at this step. HCV testing will be done in one of the referrals health centers. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center and nurses will be in charge to give result to the participant and to refer to care in case of active infection

Arm 2: Community-based testing intervention After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the household of participant. Information will be provided by the CHW using information sheet and a dedicated leaflet. If the participant agrees to participate, the signed consent form will be collected at this step before any RDT collection. In case of structural or societal barriers for household testing, it will be possible to provide testing in a specific location in the village. The onsite visits will be planned with the head of village who will be in charge to inform the population about the study. In case of absence of participant during the first visit, a second visit will be scheduled. In absence of participant during the second visit, no additional visit will be planned. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS, dried at ambient temperature and put in an individual plastic bag with the ID number and sent to Phnom Penh (Rodolphe Merieux laboratory) for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center and nurses will be in charge to give result to the participant and to refer to care in case of active infection.

Treatment phase For positive HCV RNA, a consultation in the Provincial Hospital will be planned. The Baseline assessment will include questionnaires (risk behaviours and socio-economic status), clinical exam, blood sampling and liver ultrasound. Symptomatic cirrhotic patients will be referred to a National Hospital in Phnom Penh to a hepatology department. For the others patients, DAA treatment using sofosbuvir and daclatasvir combination for 12 weeks (Cambodian Essential Medicine List 2018) will be proposed, after checking the result of creatinine and the possible drug-drug interactions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All persons aged more than 40 years old
  • Residing in the study area
  • Informed consent obtained with oral information given and explained and the consent form signed by the participant and the nurse hired by the study at the latest the time of the RDT realization

Exclusion criteria

  • Known positive HCV status with previous HCV treatment
  • Severe disease present at inclusion involving life threatening
  • Concurrent participation in any other clinical study without written agreement of the two study teams

Treatment and study plan

Community-based HCV rapid test

Other

HCV rapid tests will be done in the village

Facility-based HCV rapid test

Other

HCV rapid tests will be done in the health center

Plasmatic HCV viral load

Other

HCV viral load will be done in provincial hospital on plasma using GenXpert

DBS HCV viral load

Other

HCV viral load will be done in Phnom Penh by DBS using Omunis kit

Primary outcomes

  1. Combined-testing uptake

    Time frame: 12 months

    Combined-testing uptake defined as the number of persons tested for HCV RDT AND HCV RNA and aware of their status among the total number of persons eligible residing in the region where the intervention takes place

Secondary outcomes

  1. HCV antibody testing uptake

    Time frame: 12 months

    HCV antibody testing uptake defined as the number of persons tested for HCV RDT and aware of their status among the total number of persons eligible residing in the region where the intervention takes place

  2. Active case detection rate

    Time frame: 12 months

    defined as the number of persons with HCV active infection (positive HCV Ab and positive HCV RNA) and results given and explained among the total number of persons eligible residing in the region where the intervention takes place (measured and compared between the 2 arms)

  3. Linkage to care

    Time frame: 12 months

    the number of persons with at least one consultation in the Provincial Hospital among the estimated total number of persons with active infection residing in the region where the intervention takes place (measured and compared between the 2 arms)

Other outcomes

  1. Treatment uptake

    Time frame: 18 months

    the number of people initiating HCV treatment among the total number of persons with active infection linked to care (measured for the total population and not compared)

  2. Liver-related morbidity and mortality

    Time frame: 18 months

    Proportion of patients with decompensated cirrhosis, HCC (measured for the total population and not compared)

  3. Sustained virologic response 12

    Time frame: 18 months

    Proportion of patients with sustained virologic response 12 weeks after discontinuation of treatment (SVR12) (measured for the total population and not compared)

  4. Treatment failure

    Time frame: 18 months

    Proportion of patients with treatment failure defined as absence of SVR12 or missing HCV-RNA at 12 weeks post-treatment (PT12) due to treatment discontinuation for AEs or death (measured for the total population and not compared)

Sponsors and collaborators

Lead sponsor

ANRS, Emerging Infectious Diseases

Other Gov

Collaborators

  • Fondation Mérieux
  • Hopital Paul Brousse
  • Institut National de la Santé Et de la Recherche Médicale, France
  • SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD)
  • University of Health Sciences, Phnom Penh, Cambodia
  • University of Marseille

Registry information

Official study title

Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia: a Cluster Randomized Controlled Trial

Acronym: Cam-C

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 20, 2019
Registry last updated
Jun 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.